Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > ATM question and response

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jul 28, 2021 12:25pm

150 Views

Post# 33617032

RE:ATM question and response

It will pretty is to tell whether the selling has started a rather large divergence in daily volume with THTX trading volume much higher than TH and if true based on the document big blocks of trades towards end of the day...

Wino115 wrote:
On research reports, I found a legal opinion covering it here on page 6.

https://media2.mofo.com/documents/faqatthemarketofferings.pdf#:~:text=An%20at-the-market%20offering%20by%20an%20issuer%20of%20securities,make%20it%20subject%20to%20Rules%20101%20and%20102.

It's a bit complex as to whether a report is considered impartial or an offer to sell. There is a safe harbor rule that if you just include the company in your regularly published periodicals you can do it. Even thought the company controls the price and timing, it is still considered an offering and the banker is the sales agent. So the distribution period is the entire time. I guess your analyst can talk about it to clients, do due diligence, add it to publications. But you'd probably need to tone down any research report to just facts and maybe not opinion and valuation. I don't know what the customs are around this or what can be done with other "safe harbor" provisions for research. These things change a lot too. Good question for Dubuc to answer.

It also states that if there is a large block traded it may be considered material in which case it needs to be reported. What "large" means I don't know. But introducing am institution as a 5% holder would be. It also says trades can be crossed at average daily price at end of day.

My question is, should we assume all this trading will be reported and crossed on NASDAQ and not TSX? I don't know that Cantor has Canadian license. I am assuming it is all NASDAQ, in which case we clearly haven't seen any large volume yet.